![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 31-Jan-2013[ | E-mail |
Share ] Contact: Heather Buschman
hbuschman@sanfordburnham.org
858-795-5343
Sanford-Burnham Medical Research Institute
Sanford-Burnham researchers discover that tumors lacking the protein PKCz are good at surviving when nutrients are scarceopening a new therapeutic avenue that targets cancer metabolism
LA JOLLA, Calif., January 31, 2013 Cancer cells need food to survive and grow. They're very good at getting it, too, even when nutrients are scarce. Many scientists have tried killing cancer cells by taking away their favorite food, a sugar called glucose. Unfortunately, this treatment approach not only fails to work, it backfiresglucose-starved tumors actually get more aggressive. In a study published January 31 in the journal Cell, researchers at Sanford-Burnham Medical Research Institute discovered that a protein called PKC? is responsible for this paradox. The research suggests that glucose depletion therapies might work against tumors as long as the cancer cells are producing PKC?.
PKC?: critical regulator of tumor metabolism
According to this study, when PKC? is missing from cancer cells, tumors are able to use alternative nutrients. What's more, the lower the PKC? levels, the more aggressive the tumor.
"We found an interesting correlation in colon cancersif a patient's tumor doesn't produce PKC?, he has a poorer prognosis than a similar patient with the protein. We looked specifically at colon cancer in this study, but it's likely also true for other tumor types," said Jorge Moscat, Ph.D., a professor in Sanford-Burnham's National Cancer Institute-designated Cancer Center. Moscat led the study in close collaboration with Sanford-Burnham colleague Maria Diaz-Meco, Ph.D.
PKC? keeps tumors addicted to glucose, and under control
Although most cancer cells love glucose, tumors lacking PKC? grow even better in the absence of this nutrient. Using human tumor samples and a mouse model of colon cancer, Moscat and his team determined this growth-without-glucose paradox is because PKC?-deficient tumors are able to reprogram their metabolism to use glutamine, another nutrient, instead.
Without PKC? around to keep them addicted to glucose, these tumors kick-start a new metabolic pathway. This altered metabolism helps PKC?-deficient cancer cells survive in conditions that would otherwise be lethal.
"If we can find an effective way to add PKC? back to tumors that lack it, we'd make them less suited for survival and more sensitive to current therapies," Moscat said.
###
This study was funded by the U.S. National Institutes of HealthNational Cancer Institute grants R01CA132847, R01CA134530, R21CA147978 and 5P30CA030199-31; National Institute of Allergy and Infectious Diseases grant R01AI072581; and National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK088107.
The study was co-authored by Li Ma, Sanford-Burnham; Yongzhen Tao, Sanford-Burnham; Angeles Duran, Sanford-Burnham; Victoria Llado, Sanford-Burnham; Anita Galvez, University of Cincinnati Medical College; Jennifer F.Barger, University of Cincinnati Medical College; Elias A. Castilla, University of Cincinnati Medical College; Jing Chen, University of Cincinnati Medical College; Tomoko Yajima, Sanford-Burnham; Aleksey Porollo, University of Cincinnati Medical College; Mario Medvedovic, University of Cincinnati Medical College; Laurence M. Brill, Sanford-Burnham; David R. Plas, University of Cincinnati Medical College; Stefan J. Riedl, Sanford-Burnham; Michael Leitges, University of Oslo; Maria T. Diaz-Meco, Sanford-Burnham; Adam D. Richardson, Sanford-Burnham; and Jorge Moscat, Sanford-Burnham.
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. The Institute consistently ranks among the top five organizations worldwide for its scientific impact in the fields of biology and biochemistry (defined by citations per publication) and currently ranks third in the nation in NIH funding among all laboratory-based research institutes. Sanford-Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies. Sanford-Burnham is a U.S.-based, nonprofit public benefit corporation, with operations in San Diego (La Jolla), California and Orlando (Lake Nona), Florida. For more information, news and events, please visit us at sanfordburnham.org.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 31-Jan-2013[ | E-mail |
Share ] Contact: Heather Buschman
hbuschman@sanfordburnham.org
858-795-5343
Sanford-Burnham Medical Research Institute
Sanford-Burnham researchers discover that tumors lacking the protein PKCz are good at surviving when nutrients are scarceopening a new therapeutic avenue that targets cancer metabolism
LA JOLLA, Calif., January 31, 2013 Cancer cells need food to survive and grow. They're very good at getting it, too, even when nutrients are scarce. Many scientists have tried killing cancer cells by taking away their favorite food, a sugar called glucose. Unfortunately, this treatment approach not only fails to work, it backfiresglucose-starved tumors actually get more aggressive. In a study published January 31 in the journal Cell, researchers at Sanford-Burnham Medical Research Institute discovered that a protein called PKC? is responsible for this paradox. The research suggests that glucose depletion therapies might work against tumors as long as the cancer cells are producing PKC?.
PKC?: critical regulator of tumor metabolism
According to this study, when PKC? is missing from cancer cells, tumors are able to use alternative nutrients. What's more, the lower the PKC? levels, the more aggressive the tumor.
"We found an interesting correlation in colon cancersif a patient's tumor doesn't produce PKC?, he has a poorer prognosis than a similar patient with the protein. We looked specifically at colon cancer in this study, but it's likely also true for other tumor types," said Jorge Moscat, Ph.D., a professor in Sanford-Burnham's National Cancer Institute-designated Cancer Center. Moscat led the study in close collaboration with Sanford-Burnham colleague Maria Diaz-Meco, Ph.D.
PKC? keeps tumors addicted to glucose, and under control
Although most cancer cells love glucose, tumors lacking PKC? grow even better in the absence of this nutrient. Using human tumor samples and a mouse model of colon cancer, Moscat and his team determined this growth-without-glucose paradox is because PKC?-deficient tumors are able to reprogram their metabolism to use glutamine, another nutrient, instead.
Without PKC? around to keep them addicted to glucose, these tumors kick-start a new metabolic pathway. This altered metabolism helps PKC?-deficient cancer cells survive in conditions that would otherwise be lethal.
"If we can find an effective way to add PKC? back to tumors that lack it, we'd make them less suited for survival and more sensitive to current therapies," Moscat said.
###
This study was funded by the U.S. National Institutes of HealthNational Cancer Institute grants R01CA132847, R01CA134530, R21CA147978 and 5P30CA030199-31; National Institute of Allergy and Infectious Diseases grant R01AI072581; and National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK088107.
The study was co-authored by Li Ma, Sanford-Burnham; Yongzhen Tao, Sanford-Burnham; Angeles Duran, Sanford-Burnham; Victoria Llado, Sanford-Burnham; Anita Galvez, University of Cincinnati Medical College; Jennifer F.Barger, University of Cincinnati Medical College; Elias A. Castilla, University of Cincinnati Medical College; Jing Chen, University of Cincinnati Medical College; Tomoko Yajima, Sanford-Burnham; Aleksey Porollo, University of Cincinnati Medical College; Mario Medvedovic, University of Cincinnati Medical College; Laurence M. Brill, Sanford-Burnham; David R. Plas, University of Cincinnati Medical College; Stefan J. Riedl, Sanford-Burnham; Michael Leitges, University of Oslo; Maria T. Diaz-Meco, Sanford-Burnham; Adam D. Richardson, Sanford-Burnham; and Jorge Moscat, Sanford-Burnham.
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. The Institute consistently ranks among the top five organizations worldwide for its scientific impact in the fields of biology and biochemistry (defined by citations per publication) and currently ranks third in the nation in NIH funding among all laboratory-based research institutes. Sanford-Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies. Sanford-Burnham is a U.S.-based, nonprofit public benefit corporation, with operations in San Diego (La Jolla), California and Orlando (Lake Nona), Florida. For more information, news and events, please visit us at sanfordburnham.org.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-01/smri-hcc013013.php
Freddy E NHL lockout Honey Boo Boo pirate bay Psalms 91 once upon a time once upon a time
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.